Beltran, Himisha

Publications

Sort by

Co-Author Network

selected publications

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Conference Paper GET IT
Times cited: 125
Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine differentiation in recipient cancer cells. Journal of extracellular vesicles. 2020 Academic Article GET IT
Times cited: 41
ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. Bioinformatics (Oxford, England). 2020 Academic Article GET IT
Times cited: 5
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 88
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Molecular oncology. 2020 Academic Article GET IT
Times cited: 15
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular cancer therapeutics. 2020 Academic Article GET IT
Times cited: 32
Docetaxel for Early Prostate Cancer: What Have We Learned?. European urology. 2020 Editorial Article GET IT
Times cited: 3
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO oncology practice. 2020 Academic Article GET IT
Times cited: 7
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European urology. 2020 Conference Paper GET IT
Times cited: 254
Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 45
Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 Academic Article GET IT
Times cited: 8
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 107
Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019 Academic Article GET IT
Times cited: 43
Towards precision oncology in advanced prostate cancer. Nature reviews. Urology. 2019 Review GET IT
Times cited: 122
The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. European urology. 2019 Editorial Article GET IT
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
Clinical features of neuroendocrine prostate cancer. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 138
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 35
Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 10
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 105
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 139
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature communications. 2019 Academic Article GET IT
Times cited: 102
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 84
Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nature genetics. 2019 Article GET IT
Times cited: 5
Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget. 2019 Academic Article GET IT
Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. European urology oncology. 2019 Academic Article GET IT
Times cited: 11
Retinoblastoma Loss in Cancer: Casting a Wider Net. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Comment GET IT
Times cited: 4
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer cell. 2019 Article GET IT
Times cited: 17
Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 561
Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. EBioMedicine. 2019 Academic Article GET IT
Times cited: 28
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019 Academic Article GET IT
Times cited: 73
Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. 2019 GET IT
Times cited: 3
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer cell. 2019 Academic Article GET IT
Times cited: 46
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science translational medicine. 2019 Academic Article GET IT
Times cited: 83
Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer cell. 2019 Academic Article GET IT
Times cited: 105
Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. 2019 GET IT
Times cited: 5
Biological Evolution of Castration-resistant Prostate Cancer. European urology focus. 2019 Review GET IT
Times cited: 53
Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harbor perspectives in medicine. 2019 Review GET IT
Times cited: 56
The application of precision medicine in diagnosing familial Mediterranean fever. Leukemia & lymphoma. 2019 Letter GET IT
ONECUT2 is a driver of neuroendocrine prostate cancer. Nature communications. 2019 Academic Article GET IT
Times cited: 116
Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2018 Academic Article GET IT
Times cited: 6
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 33
Publisher Correction: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018 Academic Article GET IT
Times cited: 2
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Scientific reports. 2018 Academic Article GET IT
Times cited: 18
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 130
The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. Journal of personalized medicine. 2018 Review GET IT
Times cited: 64
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature communications. 2018 Academic Article GET IT
Times cited: 75
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 110
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. The Journal of pathology. 2018 Academic Article GET IT
Times cited: 28
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 20
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 368
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018 Academic Article GET IT
Times cited: 353
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 2
Patient derived organoids to model rare prostate cancer phenotypes. Nature communications. 2018 Academic Article GET IT
Times cited: 203
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. GigaScience. 2018 Academic Article GET IT
Times cited: 46
CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2018 Academic Article GET IT
The long tail of oncogenic drivers in prostate cancer. Nature genetics. 2018 Academic Article GET IT
Times cited: 458
Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nature reviews. Urology. 2018 Review GET IT
Times cited: 214
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European urology. 2018 Academic Article GET IT
Times cited: 90
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 6
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2017 Academic Article GET IT
Times cited: 33
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer cell. 2017 Academic Article GET IT
Times cited: 45
Rapid autopsy of a patient with recurrent anaplastic ependymoma. 2017 GET IT
Times cited: 4
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 60
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European urology. 2017 Conference Paper GET IT
Times cited: 367
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 584
Biology and evolution of poorly differentiated neuroendocrine tumors. Nature medicine. 2017 Academic Article GET IT
Times cited: 126
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harbor molecular case studies. 2017 Academic Article GET IT
Times cited: 20
Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations. Genome biology. 2017 Academic Article GET IT
Emerging Variants of Castration-Resistant Prostate Cancer. Current oncology reports. 2017 Review GET IT
Times cited: 116
Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nature biotechnology. 2017 Academic Article GET IT
Times cited: 156
On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. Anticancer research. 2017 Academic Article GET IT
Times cited: 5
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer discovery. 2017 Academic Article GET IT
Times cited: 589
The clone wars. Science translational medicine. 2017 Comment GET IT
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.). 2017 Academic Article GET IT
Times cited: 594
Prostate cancer in 2016: Improved outcomes and precision medicine come within reach. Nature reviews. Urology. 2017 Review GET IT
Times cited: 3
Unleashing the wrath of Ras. Science translational medicine. 2017 Comment GET IT
Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2017 Review GET IT
Times cited: 9
Synthetic lethality and beyond. Science translational medicine. 2016 Comment GET IT
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer discovery. 2016 Academic Article GET IT
Times cited: 217
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature genetics. 2016 Academic Article GET IT
Times cited: 201
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer cell. 2016 Academic Article GET IT
Times cited: 327
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ genomic medicine. 2016 Academic Article GET IT
Times cited: 58
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 1009
Update on the biology and management of neuroendocrine prostate cancer. Clinical advances in hematology & oncology : H&O. 2016 Article GET IT
Times cited: 10
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. European urology. 2016 Academic Article GET IT
Times cited: 118
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 9
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. Thrombosis research. 2016 Academic Article GET IT
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature medicine. 2016 Academic Article GET IT
Times cited: 933
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2016 Academic Article GET IT
Times cited: 24
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 101
An emerging role for cytopathology in precision oncology. Cancer cytopathology. 2015 Academic Article GET IT
Times cited: 18
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell reports. 2015 Academic Article GET IT
Times cited: 176
Prostate cancer: Intrapatient heterogeneity in prostate cancer. Nature reviews. Urology. 2015 Comment GET IT
Times cited: 17
Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Article GET IT
Times cited: 340
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA oncology. 2015 Academic Article GET IT
Times cited: 216
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Conference Paper GET IT
Times cited: 257
Integrative clinical genomics of advanced prostate cancer. Cell. 2015 Academic Article GET IT
Times cited: 2094
CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget. 2015 Academic Article GET IT
Times cited: 20
Prioritizing precision medicine for prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Editorial Article GET IT
Times cited: 7
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Review GET IT
Times cited: 47
ERG induces taxane resistance in castration-resistant prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 91
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 494
Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Academic Article GET IT
Times cited: 983
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome biology. 2014 Academic Article GET IT
Times cited: 76
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Human pathology. 2014 Academic Article GET IT
Times cited: 24
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. The American journal of surgical pathology. 2014 Academic Article GET IT
Times cited: 362
Aggressive variants of castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Review GET IT
Times cited: 285
The many faces of neuroendocrine differentiation in prostate cancer progression. Frontiers in oncology. 2014 Review GET IT
Times cited: 906
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential. Molecular cancer research : MCR. 2014 Review GET IT
Times cited: 104
Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib. Asian journal of andrology. 2014 Comment GET IT
Times cited: 1
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer research. 2013 Academic Article GET IT
Times cited: 266
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature biotechnology. 2013 Academic Article GET IT
Times cited: 1491
Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 43
Punctuated evolution of prostate cancer genomes. Cell. 2013 Academic Article GET IT
Times cited: 906
Epigenomic alterations in localized and advanced prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 61
DNA mismatch repair in prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 10
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 190
New strategies in prostate cancer: translating genomics into the clinic. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Review GET IT
Times cited: 47
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer research. 2012 Academic Article GET IT
Times cited: 150
Challenges in recognizing treatment-related neuroendocrine prostate cancer. 2012 GET IT
Times cited: 163
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. European urology. 2012 Academic Article GET IT
Times cited: 328
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. The Journal of pathology. 2012 Academic Article GET IT
Times cited: 148
Editorial comment. The Journal of urology. 2012 Editorial Article GET IT
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 40
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. 2012 GET IT
Times cited: 30
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer discovery. 2011 Academic Article GET IT
Times cited: 633
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU international. 2011 Review GET IT
Times cited: 22
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. Asian journal of andrology. 2011 Academic Article GET IT
Times cited: 1
New therapies for castration-resistant prostate cancer: efficacy and safety. European urology. 2011 Review GET IT
Times cited: 123
Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosis. 2010 GET IT
Times cited: 6
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010 Academic Article GET IT
Times cited: 122

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Co-Investigator 2017 - 2023

Personalized in vitro models to advance precision medicine awarded by National Cancer Institute Key Personnel 2019 - 2023

more ...

less ...

Background

education and training

M.D., New York Medical College 2004
B.S., University of Oregon 2000

Contact

full name

Himisha Beltran

primary email

hip9004@med.cornell.edu

VIVO Weill Cornell Medical College

Himisha Beltran Adjunct Associate Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email